Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bicara Therapeutics Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing bifunctional therapies for solid tumors. Forms 8-K record financial results, business highlights, ficerafusp alfa clinical updates, material definitive agreements and other events, including common stock and pre-funded warrant financing.
The company’s proxy materials cover annual meeting proposals, board-class elections, auditor ratification and governance matters for an emerging growth company. The filings also describe capital-structure actions and formal exhibits tied to press releases, underwriting agreements and shareholder voting matters.
BCAX reports an issuer-related planned sale of 5,500 common shares tied to an exercise of stock options to be effected on 03/25/2026 for cash. The filing also discloses recent open-market sales by David Raben: 200 shares on 03/03/2026 for $3,690.00 and 16,300 shares on 03/04/2026 for $301,920.01.
Bicara Therapeutics Inc. Chief Financial Officer Hyep Ivan exercised stock options and sold shares in a pre-planned transaction. On March 23, 2026, he exercised options for 9,200 shares of common stock at an exercise price of $3.7898 per share, then sold the same 9,200 shares at a weighted average price of $18.5161 per share in multiple trades between $18.15 and $18.84. The sale was carried out under a Rule 10b5-1 trading plan adopted on February 13, 2025, indicating the trades were pre-scheduled rather than opportunistic. Following these transactions, Ivan directly owned 145,355 shares of Bicara Therapeutics common stock. The exercised options were part of a grant vesting in sixteen equal quarterly installments after April 5, 2023 and are scheduled to expire on April 5, 2033.
BCAX insider reported proposed sale of 9,200 common shares by exercise of stock options, listed as to be sold on 03/23/2026 for cash. The filing also lists three reported dispositions in the prior three months: 01/22/2026 1,882 shares, 03/03/2026 13,555 shares, and 03/04/2026 2,963 shares.
Bicara Therapeutics Inc. director and Chief Executive Officer Claire Mazumdar exercised stock options and sold the related shares over three days. She exercised options for a total of 15,000 shares of Common Stock at an exercise price of $3.7898 per share, then sold 15,000 shares in open-market transactions at weighted-average prices between $18.73 and $19.26, as disclosed in the price ranges. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. Following the transactions, she holds 339,392 shares of Common Stock directly.
BCAX affiliate reported planned sale of Common Stock and multiple recent dispositions. The filing lists 03/20/2026 for an intended sale of 1,596 shares via exercise of stock options for cash. The excerpt also lists past dispositions over the prior three months totaling specific tranches on 03/04/2026, 03/05/2026, 03/06/2026, 03/09/2026, 03/18/2026, and 03/19/2026 by Claire Mazumdar with per‑trade share counts and dollar values provided.
BCAX filing reports a proposed sale of 6,905 shares of Common Stock on 03/19/2026 following an exercise of stock options for cash. The notice lists multiple prior dispositions by Claire Mazumdar in the past three months, including 3/9/2026: 36,766 shares and 3/18/2026: 6,499 shares.
BCAX affiliate files Form 144 to sell 6,499 shares. The filing states 6,499 Common shares are to be sold on 03/18/2026 following an exercise of stock options with cash proceeds to the issuer. The filing also lists recent dispositions by Claire Mazumdar: 2,631 shares on 03/04/2026, 1,786 shares on 03/05/2026, 3,817 shares on 03/06/2026, and 36,766 shares on 03/09/2026.
Bicara Therapeutics Inc.'s President and COO, Ryan Cohlhepp, exercised stock options for 8,000 shares of common stock at an exercise price of $3.7898 per share and then sold 12,500 shares of common stock at a weighted average price of $19.6571 per share. The sales were executed on March 16, 2026 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. Following these transactions, he directly holds 200,641 shares of Bicara common stock.
BCAX files Form 144 reporting proposed sales of Common stock and recent dispositions by a holder. The filing lists securities to be sold from option exercises including 05/12/2024 (4,500 shares) and 03/16/2026 (8,000 shares). It also reports actual Common stock sales by Ryan Cohlhepp on 01/15/2026 (149 shares, $2,684.98), 01/22/2026 (3,828 shares, $69,295.99), 02/25/2026 (3,631 shares, $69,132.42), and 03/03/2026 (17,392 shares, $315,892.64).
Bicara Therapeutics Inc. Chief Executive Officer Claire Mazumdar exercised options to acquire 36,766 shares of common stock at an exercise price of $3.7898 per share on March 9, 2026. She then sold 36,766 shares of common stock at a weighted average price of $19.1660 per share in open-market transactions executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. Following these transactions, she directly holds 339,392 shares of Bicara Therapeutics common stock.